Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Discovery of a CD10 negative B-progenitor in human fetal life identifies unique ontogeny-related developmental programs.

O'Byrne S, Elliott N, Rice S, Buck G, Fordham N, Garnett C, Godfrey L, Crump NT, Wright G, Inglott S, Hua P, Psaila B, Povinelli B, Knapp DJHF, Agraz-Doblas A, Bueno C, Varela I, Bennett P, Koohy H, Watt SM, Karadimitris A, Mead AJ, Ancliff P, Vyas P, Menendez P, Milne TA, Roberts I, Roy A.

Blood. 2019 Aug 5. pii: blood.2019001289. doi: 10.1182/blood.2019001289. [Epub ahead of print]

PMID:
31383639
2.

Cell-intrinsic depletion of Aml1-ETO-expressing pre-leukemic hematopoietic stem cells by K-Ras activating mutation.

Di Genua C, Norfo R, Rodriguez-Meira A, Wen WX, Drissen R, Booth CAG, Povinelli B, Repapi E, Gray N, Carrelha J, Kettyle LM, Jamieson L, Neo WH, Thongjuea S, Nerlov C, Mead AJ.

Haematologica. 2019 Apr 11. pii: haematol.2018.205351. doi: 10.3324/haematol.2018.205351. [Epub ahead of print]

3.

UK results from the myeloproliferative neoplasms (MPN) landmark survey on the symptom, emotional and economic burden of MPN.

Harrison C, Mathias J, Campbell-Drew M, Mead AJ, Pemberton-Whiteley Z, Ali S, Wadelin F, Taylor-Stokes G, Waller J, Taylor B.

Br J Haematol. 2019 Aug;186(3):e1-e4. doi: 10.1111/bjh.15839. Epub 2019 Mar 10. No abstract available.

PMID:
30854625
4.

Unravelling Intratumoral Heterogeneity through High-Sensitivity Single-Cell Mutational Analysis and Parallel RNA Sequencing.

Rodriguez-Meira A, Buck G, Clark SA, Povinelli BJ, Alcolea V, Louka E, McGowan S, Hamblin A, Sousos N, Barkas N, Giustacchini A, Psaila B, Jacobsen SEW, Thongjuea S, Mead AJ.

Mol Cell. 2019 Mar 21;73(6):1292-1305.e8. doi: 10.1016/j.molcel.2019.01.009. Epub 2019 Feb 12.

5.

Single-cell approaches reveal novel cellular pathways for megakaryocyte and erythroid differentiation.

Psaila B, Mead AJ.

Blood. 2019 Mar 28;133(13):1427-1435. doi: 10.1182/blood-2018-11-835371. Epub 2019 Feb 6. Review.

PMID:
30728145
6.

Origins of ETP leukemia.

Booth CAG, Jacobsen SEW, Mead AJ.

Oncoscience. 2018 Aug 22;5(11-12):271-272. doi: 10.18632/oncoscience.456. eCollection 2018 Nov. No abstract available.

7.

Heterogeneity in myeloproliferative neoplasms: Causes and consequences.

O'Sullivan J, Mead AJ.

Adv Biol Regul. 2019 Jan;71:55-68. doi: 10.1016/j.jbior.2018.11.007. Epub 2018 Nov 22. Review.

PMID:
30528537
8.

A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline.

McMullin MF, Harrison CN, Ali S, Cargo C, Chen F, Ewing J, Garg M, Godfrey A, S SK, McLornan DP, Nangalia J, Sekhar M, Wadelin F, Mead AJ; BSH Committee.

Br J Haematol. 2019 Jan;184(2):176-191. doi: 10.1111/bjh.15648. Epub 2018 Nov 27. No abstract available. Erratum in: Br J Haematol. 2019 Apr;185(1):198.

PMID:
30478826
9.

A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis: A British Society for Haematology Guideline.

McMullin MFF, Mead AJ, Ali S, Cargo C, Chen F, Ewing J, Garg M, Godfrey A, Knapper S, McLornan DP, Nangalia J, Sekhar M, Wadelin F, Harrison CN; British Society for Haematology Guideline.

Br J Haematol. 2019 Jan;184(2):161-175. doi: 10.1111/bjh.15647. Epub 2018 Nov 13. No abstract available.

10.

Consensus on BCR-ABL1 reporting in chronic myeloid leukaemia in the UK.

Cross NCP, White HE, Evans PAS, Hancock J, Copland M, Milojkovic D, Mason J, Craine S, Mead AJ.

Br J Haematol. 2018 Sep;182(6):777-788. doi: 10.1111/bjh.15542. Epub 2018 Aug 20. Review.

11.

Cell-extrinsic hematopoietic impact of Ezh2 inactivation in fetal liver endothelial cells.

Neo WH, Booth CAG, Azzoni E, Chi L, Delgado-Olguín P, de Bruijn MFTR, Jacobsen SEW, Mead AJ.

Blood. 2018 May 17;131(20):2223-2234. doi: 10.1182/blood-2017-10-811455. Epub 2018 Mar 19.

12.

Ezh2 and Runx1 Mutations Collaborate to Initiate Lympho-Myeloid Leukemia in Early Thymic Progenitors.

Booth CAG, Barkas N, Neo WH, Boukarabila H, Soilleux EJ, Giotopoulos G, Farnoud N, Giustacchini A, Ashley N, Carrelha J, Jamieson L, Atkinson D, Bouriez-Jones T, Prinjha RK, Milne TA, Teachey DT, Papaemmanuil E, Huntly BJP, Jacobsen SEW, Mead AJ.

Cancer Cell. 2018 Feb 12;33(2):274-291.e8. doi: 10.1016/j.ccell.2018.01.006.

13.

Canonical Notch signaling is dispensable for adult steady-state and stress myelo-erythropoiesis.

Duarte S, Woll PS, Buza-Vidas N, Chin DWL, Boukarabila H, Luís TC, Stenson L, Bouriez-Jones T, Ferry H, Mead AJ, Atkinson D, Jin S, Clark SA, Wu B, Repapi E, Gray N, Taylor S, Mutvei AP, Tsoi YL, Nerlov C, Lendahl U, Jacobsen SEW.

Blood. 2018 Apr 12;131(15):1712-1719. doi: 10.1182/blood-2017-06-788505. Epub 2018 Jan 16.

14.

Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.

Harrison CN, Mead AJ, Panchal A, Fox S, Yap C, Gbandi E, Houlton A, Alimam S, Ewing J, Wood M, Chen F, Coppell J, Panoskaltsis N, Knapper S, Ali S, Hamblin A, Scherber R, Dueck AC, Cross NCP, Mesa R, McMullin MF.

Blood. 2017 Oct 26;130(17):1889-1897. doi: 10.1182/blood-2017-05-785790. Epub 2017 Aug 9.

15.

Mbd3/NuRD controls lymphoid cell fate and inhibits tumorigenesis by repressing a B cell transcriptional program.

Loughran SJ, Comoglio F, Hamey FK, Giustacchini A, Errami Y, Earp E, Göttgens B, Jacobsen SEW, Mead AJ, Hendrich B, Green AR.

J Exp Med. 2017 Oct 2;214(10):3085-3104. doi: 10.1084/jem.20161827. Epub 2017 Sep 12.

16.

Single cell analysis of normal and leukemic hematopoiesis.

Povinelli BJ, Rodriguez-Meira A, Mead AJ.

Mol Aspects Med. 2018 Feb;59:85-94. doi: 10.1016/j.mam.2017.08.006. Epub 2017 Sep 8. Review.

17.

Niche-mediated depletion of the normal hematopoietic stem cell reservoir by Flt3-ITD-induced myeloproliferation.

Mead AJ, Neo WH, Barkas N, Matsuoka S, Giustacchini A, Facchini R, Thongjuea S, Jamieson L, Booth CAG, Fordham N, Di Genua C, Atkinson D, Chowdhury O, Repapi E, Gray N, Kharazi S, Clark SA, Bouriez T, Woll P, Suda T, Nerlov C, Jacobsen SEW.

J Exp Med. 2017 Jul 3;214(7):2005-2021. doi: 10.1084/jem.20161418. Epub 2017 Jun 21.

18.

Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia.

Giustacchini A, Thongjuea S, Barkas N, Woll PS, Povinelli BJ, Booth CAG, Sopp P, Norfo R, Rodriguez-Meira A, Ashley N, Jamieson L, Vyas P, Anderson K, Segerstolpe Å, Qian H, Olsson-Strömberg U, Mustjoki S, Sandberg R, Jacobsen SEW, Mead AJ.

Nat Med. 2017 Jun;23(6):692-702. doi: 10.1038/nm.4336. Epub 2017 May 15.

PMID:
28504724
19.

Equivalence of BCSH and WHO diagnostic criteria for ET.

Harrison CN, McMullin MF, Green AR, Mead AJ.

Leukemia. 2017 Jul;31(7):1660. doi: 10.1038/leu.2017.119. Epub 2017 May 5.

PMID:
28474678
20.

Myeloproliferative neoplasm stem cells.

Mead AJ, Mullally A.

Blood. 2017 Mar 23;129(12):1607-1616. doi: 10.1182/blood-2016-10-696005. Epub 2017 Feb 3. Review.

21.

Guideline for the investigation and management of eosinophilia.

Butt NM, Lambert J, Ali S, Beer PA, Cross NC, Duncombe A, Ewing J, Harrison CN, Knapper S, McLornan D, Mead AJ, Radia D, Bain BJ; British Committee for Standards in Haematology.

Br J Haematol. 2017 Feb;176(4):553-572. doi: 10.1111/bjh.14488. Epub 2017 Jan 23. No abstract available.

22.

Equivalence of BCSH and WHO diagnostic criteria for ET.

Harrison CN, McMullin MF, Green AR, Mead AJ.

Leukemia. 2017 Feb;31(2):527-528. doi: 10.1038/leu.2016.318. Epub 2016 Nov 29. No abstract available. Erratum in: Leukemia. 2017 Jul;31(7):1660.

PMID:
27895337
23.

Initial seeding of the embryonic thymus by immune-restricted lympho-myeloid progenitors.

Luis TC, Luc S, Mizukami T, Boukarabila H, Thongjuea S, Woll PS, Azzoni E, Giustacchini A, Lutteropp M, Bouriez-Jones T, Vaidya H, Mead AJ, Atkinson D, Böiers C, Carrelha J, Macaulay IC, Patient R, Geissmann F, Nerlov C, Sandberg R, de Bruijn MFTR, Blackburn CC, Godin I, Jacobsen SEW.

Nat Immunol. 2016 Dec;17(12):1424-1435. doi: 10.1038/ni.3576. Epub 2016 Oct 3.

24.

Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence.

Harrison CN, Talpaz M, Mead AJ.

Leuk Lymphoma. 2016 Oct;57(10):2259-67. doi: 10.1080/10428194.2016.1195501. Epub 2016 Jul 27. Review.

25.

Single-cell profiling of human megakaryocyte-erythroid progenitors identifies distinct megakaryocyte and erythroid differentiation pathways.

Psaila B, Barkas N, Iskander D, Roy A, Anderson S, Ashley N, Caputo VS, Lichtenberg J, Loaiza S, Bodine DM, Karadimitris A, Mead AJ, Roberts I.

Genome Biol. 2016 May 3;17:83. doi: 10.1186/s13059-016-0939-7.

26.

A dynamic niche provides Kit ligand in a stage-specific manner to the earliest thymocyte progenitors.

Buono M, Facchini R, Matsuoka S, Thongjuea S, Waithe D, Luis TC, Giustacchini A, Besmer P, Mead AJ, Jacobsen SE, Nerlov C.

Nat Cell Biol. 2016 Feb;18(2):157-67. doi: 10.1038/ncb3299. Epub 2016 Jan 18.

27.

Studying epigenomics in single cells: what is feasible and what can we learn?

Wills QF, Higgs DR, Mead AJ.

Epigenomics. 2015;7(8):1231-4. doi: 10.2217/epi.15.93. Epub 2015 Dec 8. No abstract available.

28.

Clinical potential of pacritinib in the treatment of myelofibrosis.

Duenas-Perez AB, Mead AJ.

Ther Adv Hematol. 2015 Aug;6(4):186-201. doi: 10.1177/2040620715586527. Review.

29.

Application of single-cell genomics in cancer: promise and challenges.

Wills QF, Mead AJ.

Hum Mol Genet. 2015 Oct 15;24(R1):R74-84. doi: 10.1093/hmg/ddv235. Epub 2015 Jun 25. Review.

30.

Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms.

Tapper W, Jones AV, Kralovics R, Harutyunyan AS, Zoi K, Leung W, Godfrey AL, Guglielmelli P, Callaway A, Ward D, Aranaz P, White HE, Waghorn K, Lin F, Chase A, Baxter EJ, Maclean C, Nangalia J, Chen E, Evans P, Short M, Jack A, Wallis L, Oscier D, Duncombe AS, Schuh A, Mead AJ, Griffiths M, Ewing J, Gale RE, Schnittger S, Haferlach T, Stegelmann F, Döhner K, Grallert H, Strauch K, Tanaka T, Bandinelli S, Giannopoulos A, Pieri L, Mannarelli C, Gisslinger H, Barosi G, Cazzola M, Reiter A, Harrison C, Campbell P, Green AR, Vannucchi A, Cross NC.

Nat Commun. 2015 Apr 7;6:6691. doi: 10.1038/ncomms7691.

31.

Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial.

Mead AJ, Milojkovic D, Knapper S, Garg M, Chacko J, Farquharson M, Yin J, Ali S, Clark RE, Andrews C, Dawson MK, Harrison C.

Br J Haematol. 2015 Jul;170(1):29-39. doi: 10.1111/bjh.13379. Epub 2015 Mar 30.

PMID:
25824940
32.

Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012.

Reilly JT, McMullin MF, Beer PA, Butt N, Conneally E, Duncombe AS, Green AR, Mikhaeel G, Gilleece MH, Knapper S, Mead AJ, Mesa RA, Sekhar M, Harrison CN.

Br J Haematol. 2014 Nov;167(3):418-20. doi: 10.1111/bjh.12985. Epub 2014 Jun 25. No abstract available.

PMID:
24961987
33.

Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo.

Woll PS, Kjällquist U, Chowdhury O, Doolittle H, Wedge DC, Thongjuea S, Erlandsson R, Ngara M, Anderson K, Deng Q, Mead AJ, Stenson L, Giustacchini A, Duarte S, Giannoulatou E, Taylor S, Karimi M, Scharenberg C, Mortera-Blanco T, Macaulay IC, Clark SA, Dybedal I, Josefsen D, Fenaux P, Hokland P, Holm MS, Cazzola M, Malcovati L, Tauro S, Bowen D, Boultwood J, Pellagatti A, Pimanda JE, Unnikrishnan A, Vyas P, Göhring G, Schlegelberger B, Tobiasson M, Kvalheim G, Constantinescu SN, Nerlov C, Nilsson L, Campbell PJ, Sandberg R, Papaemmanuil E, Hellström-Lindberg E, Linnarsson S, Jacobsen SE.

Cancer Cell. 2014 Jun 16;25(6):794-808. doi: 10.1016/j.ccr.2014.03.036. Epub 2014 May 15. Erratum in: Cancer Cell. 2014 Jun 16;25(6):861. Cancer Cell. 2015 Apr 13;27(4):603-5.

34.

Erythropoietin guides multipotent hematopoietic progenitor cells toward an erythroid fate.

Grover A, Mancini E, Moore S, Mead AJ, Atkinson D, Rasmussen KD, O'Carroll D, Jacobsen SE, Nerlov C.

J Exp Med. 2014 Feb 10;211(2):181-8. doi: 10.1084/jem.20131189. Epub 2014 Feb 3.

35.

Lymphomyeloid contribution of an immune-restricted progenitor emerging prior to definitive hematopoietic stem cells.

Böiers C, Carrelha J, Lutteropp M, Luc S, Green JC, Azzoni E, Woll PS, Mead AJ, Hultquist A, Swiers G, Perdiguero EG, Macaulay IC, Melchiori L, Luis TC, Kharazi S, Bouriez-Jones T, Deng Q, Pontén A, Atkinson D, Jensen CT, Sitnicka E, Geissmann F, Godin I, Sandberg R, de Bruijn MF, Jacobsen SE.

Cell Stem Cell. 2013 Nov 7;13(5):535-48. doi: 10.1016/j.stem.2013.08.012. Epub 2013 Sep 19.

36.

Germline counterparts of oncogenic mutations: who gives a JAK?.

Mead AJ, Constantinescu SN, Jacobsen SE.

Oncotarget. 2013 Jun;4(6):814-5. No abstract available.

37.

FLT3-ITDs instruct a myeloid differentiation and transformation bias in lymphomyeloid multipotent progenitors.

Mead AJ, Kharazi S, Atkinson D, Macaulay I, Pecquet C, Loughran S, Lutteropp M, Woll P, Chowdhury O, Luc S, Buza-Vidas N, Ferry H, Clark SA, Goardon N, Vyas P, Constantinescu SN, Sitnicka E, Nerlov C, Jacobsen SE.

Cell Rep. 2013 Jun 27;3(6):1766-76. doi: 10.1016/j.celrep.2013.04.031. Epub 2013 May 30.

38.

Impact of isolated germline JAK2V617I mutation on human hematopoiesis.

Mead AJ, Chowdhury O, Pecquet C, Dusa A, Woll P, Atkinson D, Burns A, Score J, Rugless M, Clifford R, Moule S, Bienz N, Vyas P, Cross N, Gale RE, Henderson S, Constantinescu SN, Schuh A, Jacobsen SE.

Blood. 2013 May 16;121(20):4156-65. doi: 10.1182/blood-2012-05-430926. Epub 2013 Mar 27.

39.

Perturbation of fetal liver hematopoietic stem and progenitor cell development by trisomy 21.

Roy A, Cowan G, Mead AJ, Filippi S, Bohn G, Chaidos A, Tunstall O, Chan JK, Choolani M, Bennett P, Kumar S, Atkinson D, Wyatt-Ashmead J, Hu M, Stumpf MP, Goudevenou K, O'Connor D, Chou ST, Weiss MJ, Karadimitris A, Jacobsen SE, Vyas P, Roberts I.

Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17579-84. doi: 10.1073/pnas.1211405109. Epub 2012 Oct 8.

40.

Dicer is selectively important for the earliest stages of erythroid development.

Buza-Vidas N, Cismasiu VB, Moore S, Mead AJ, Woll PS, Lutteropp M, Melchiori L, Luc S, Bouriez-Jones T, Atkinson D, O'Carroll D, Jacobsen SE, Nerlov C.

Blood. 2012 Sep 20;120(12):2412-6. Epub 2012 Aug 6.

41.

Allogeneic stem cell transplantation for myelofibrosis in 2012.

McLornan DP, Mead AJ, Jackson G, Harrison CN.

Br J Haematol. 2012 May;157(4):413-25. doi: 10.1111/j.1365-2141.2012.09107.x. Epub 2012 Mar 29. Review.

PMID:
22463701
42.

Germline JAK2 mutation in a family with hereditary thrombocytosis.

Mead AJ, Rugless MJ, Jacobsen SE, Schuh A.

N Engl J Med. 2012 Mar 8;366(10):967-9. doi: 10.1056/NEJMc1200349. No abstract available.

PMID:
22397670
43.

The earliest thymic T cell progenitors sustain B cell and myeloid lineage potential.

Luc S, Luis TC, Boukarabila H, Macaulay IC, Buza-Vidas N, Bouriez-Jones T, Lutteropp M, Woll PS, Loughran SJ, Mead AJ, Hultquist A, Brown J, Mizukami T, Matsuoka S, Ferry H, Anderson K, Duarte S, Atkinson D, Soneji S, Domanski A, Farley A, Sanjuan-Pla A, Carella C, Patient R, de Bruijn M, Enver T, Nerlov C, Blackburn C, Godin I, Jacobsen SE.

Nat Immunol. 2012 Feb 19;13(4):412-9. doi: 10.1038/ni.2255.

44.

Impact of gene dosage, loss of wild-type allele, and FLT3 ligand on Flt3-ITD-induced myeloproliferation.

Kharazi S, Mead AJ, Mansour A, Hultquist A, Böiers C, Luc S, Buza-Vidas N, Ma Z, Ferry H, Atkinson D, Reckzeh K, Masson K, Cammenga J, Rönnstrand L, Arai F, Suda T, Nerlov C, Sitnicka E, Jacobsen SE.

Blood. 2011 Sep 29;118(13):3613-21. doi: 10.1182/blood-2010-06-289207. Epub 2011 Aug 2.

45.

Persistent malignant stem cells in del(5q) myelodysplasia in remission.

Tehranchi R, Woll PS, Anderson K, Buza-Vidas N, Mizukami T, Mead AJ, Astrand-Grundström I, Strömbeck B, Horvat A, Ferry H, Dhanda RS, Hast R, Rydén T, Vyas P, Göhring G, Schlegelberger B, Johansson B, Hellström-Lindberg E, List A, Nilsson L, Jacobsen SE.

N Engl J Med. 2010 Sep 9;363(11):1025-37. doi: 10.1056/NEJMoa0912228.

46.

HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning.

Mead AJ, Thomson KJ, Morris EC, Mohamedbhai S, Denovan S, Orti G, Fielding AK, Kottaridis PD, Hough R, Chakraverty R, Linch DC, Mackinnon S, Peggs KS.

Blood. 2010 Jun 24;115(25):5147-53. doi: 10.1182/blood-2010-01-265413. Epub 2010 Apr 6.

47.
48.

Conflicting data on the prognostic significance of FLT3/TKD mutations in acute myeloid leukemia might be related to the incidence of biallelic disease.

Mead AJ, Gale RE, Hills RK, Gupta M, Young BD, Burnett AK, Linch DC.

Blood. 2008 Jul 15;112(2):444-5; author reply 445. doi: 10.1182/blood-2008-02-140392. No abstract available.

49.

Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication.

Mead AJ, Gale RE, Kottaridis PD, Matsuda S, Khwaja A, Linch DC.

Br J Haematol. 2008 May;141(4):454-60. doi: 10.1111/j.1365-2141.2008.07025.x. Epub 2008 Mar 12.

PMID:
18341639
50.

The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.

Gale RE, Green C, Allen C, Mead AJ, Burnett AK, Hills RK, Linch DC; Medical Research Council Adult Leukaemia Working Party.

Blood. 2008 Mar 1;111(5):2776-84. Epub 2007 Oct 23.

Supplemental Content

Support Center